Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06546358 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Quetiapine Versus Trazadone in Women With Postpartum Depression

StatusNot Yet Recruiting
PhaseEarly Phase 1
Started2024-09
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 9, 2024 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Postpartum depression is a serious disorder that affects approximately 17% of women who have recently given birth. Untreated postpartum depression can negatively affect the mother, the infant, and the family. Lack of sleep is common after delivery and can trigger or worsen depression in some women. Trazodone is used for sleeplessness and depression, but it has not been studied for postpartum depression. There is preliminary evidence that quetiapine, another drug used for depression and sleeplessness, may be effective for postpartum depression. We are planning a study to compare the effectiveness and side effects of quetiapine and trazodone in women with postpartum depression. The results of this study will help us carry out larger studies comparing these drugs with a placebo (a sugar pill) in postpartum depression. We expect the results of our study will improve the mental health of mothers and the well-being of their babies and make it easier for healthcare staff to select the right drug for women with postpartum depression.
Trial Details
NCT Number NCT06546358
Lead Sponsor London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Conditions Postpartum Depression
Enrollment 50 participants
Start Date 2024-09
Primary Completion 2025-09 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2024-08-09